Clinical Commander

Back to dossier
derm.skin-abscess.core.v1PRODUCTION
derm.skin-abscess.core.v1

Cutaneous abscess / furuncle / carbuncle (I&D-primary purulent SSTI)

dermatologyacuteadultpediatric
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Purulent vs non-purulent SSTI pivot (IDSA 2014 SSTI Stevens PMID 24973422 — distinct pathways); abscess/furuncle/carbuncle → I&D-primary; exclude necrotizing fasciitis (id.necrotising-fasciitis.core.v1) and non-purulent cellulitis (id.cellulitis.core.v1)

Inputs
0
Actions
0
Advance rule
Set
Advance when

purulent collection confirmed and scope set

Patient inputs (18)

Fluctuance is the cardinal sign that a collection is drainable — drives the I&D-vs-observe decision (IDSA 2014 SSTI Stevens PMID 24973422 — incision & drainage is primary therapy for abscess)

Fever drives severity class (moderate→severe purulent SSTI) and adjunctive-antibiotic decision (IDSA 2014 SSTI Stevens PMID 24973422)

Tachycardia is a qSOFA/SIRS element when systemic toxicity present (SSC 2026)

Prior MRSA / household MRSA drives adjunctive agent choice and decolonization (Moran NEJM 2006 PMID 16914702; Fritz CID 2012 PMID 22198793)

Diabetes lowers the threshold for adjunctive antibiotics and admission; impaired healing (IDSA 2014 SSTI Stevens PMID 24973422)

Neutropenia / transplant / biologic / advanced HIV → adjunctive antibiotics after I&D, lower admission threshold, broader pathogens (IDSA 2014 SSTI Stevens PMID 24973422)

Pain out of proportion, dusky skin, crepitus, bullae → necrotizing fasciitis red flag — do NOT incise at bedside; emergent surgery (IDSA 2014 SSTI Stevens PMID 24973422)

Facial danger triangle / perirectal / perineal / hand / deep-space location changes procedure setting (specialist/OR) and risk (IDSA 2014 SSTI Stevens PMID 24973422)

Hypotension → sepsis pathway, route to id.sepsis.core.v1 SSC Hour-1 bundle (SSC 2026)

Diameter >2 cm is a key adjunctive-antibiotic and disposition discriminator (Talan NEJM 2016 PMID 26962903; IDSA 2014 SSTI Stevens PMID 24973422)

Surrounding cellulitis upgrades severity and triggers adjunctive systemic antibiotics after I&D (IDSA 2014 SSTI Stevens PMID 24973422)

POCUS distinguishes drainable abscess from cellulitis when exam equivocal; finds occult/deep collections (Subramaniam Acad Emerg Med 2016 PMID 27770490)

PWID injection-site abscess: high polymicrobial/anaerobic + occult deep extension; consider US + broader coverage (IDSA 2014 SSTI Stevens PMID 24973422)

≥2 episodes/year defines recurrent furunculosis → decolonization candidacy and HS reconsideration (Fritz CID 2012 PMID 22198793; Alikhan JAAD 2019 PMID 30872156)

Leukocytosis supports systemic involvement / severe purulent SSTI class (IDSA 2014 SSTI Stevens PMID 24973422)

CRP/PCT supports severity assessment and response trend when systemic features present (IDSA 2014 SSTI Stevens PMID 24973422)

Antibiotic safety: avoid TMP-SMX (1st trimester / near term), tetracyclines; clindamycin pregnancy-acceptable (IDSA 2014 SSTI Stevens PMID 24973422)

TMP-SMX and vancomycin renal dose adjustment; baseline before TMP-SMX (hyperkalemia/AKI risk) (IDSA 2014 SSTI Stevens PMID 24973422)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (8)

8 need judgement
  • informationallife_threateningnecrotizing_features_at_abscess_site
    Pain out of proportion, dusky/anaesthetic skin, hemorrhagic bullae, crepitus, "dishwater" drainage, or rapidly spreading erythema around the collection (IDSA 2014 SSTI Stevens PMID 24973422)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresepsis_with_abscess_source
    qSOFA ≥2 OR SIRS ≥2 with cutaneous abscess as the source (SSC 2026; IDSA 2014 SSTI Stevens PMID 24973422)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredanger_zone_or_deep_space_abscess
    Facial danger triangle, perirectal/perineal, hand/deep palmar space, periorbital, or deep-space abscess (IDSA 2014 SSTI Stevens PMID 24973422)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereimmunocompromised_host_abscess
    Neutropenic (ANC <500), transplant, biologic/immunosuppressant, advanced HIV, or poorly controlled diabetes with cutaneous abscess (IDSA 2014 SSTI Stevens PMID 24973422)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverefailed_initial_incision_and_drainage
    No improvement or worsening 48–72 h after adequate-appearing I&D ± oral antibiotics — persistent fluctuance, expanding erythema, new systemic features (IDSA 2014 SSTI Stevens PMID 24973422)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatelarge_or_multiple_abscesses_needing_or
    Single abscess >5 cm, multiple/multiloculated abscesses, or carbuncle requiring operative drainage / not drainable at bedside (IDSA 2014 SSTI Stevens PMID 24973422; Talan NEJM 2016 PMID 26962903)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepwid_injection_site_abscess
    Injection-site abscess in a person who injects drugs — high polymicrobial/anaerobic burden, occult deep extension, and endovascular seeding risk (IDSA 2014 SSTI Stevens PMID 24973422)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildrecurrent_furunculosis_decolonization_candidate
    ≥2 cutaneous abscesses/furuncles per year, or household clustering (Fritz CID 2012 PMID 22198793; IDSA 2014 SSTI Stevens PMID 24973422)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives screening
Loading…

Recommended regimen

I&D-primary + severity-tiered adjunctive antibiotics
axis: abscess_source_control_and_adjunctive_antibioticsstep 1 - Mild — simple drained abscess, healthy host
Selected step "Mild — simple drained abscess, healthy host" — Fluctuant abscess <2 cm, no surrounding cellulitis, no systemic features, immunocompetent — I&D alone is curative; antibiotics NOT routinely indicated (Schmitz Ann Emerg Med 2010 PMID 20346539; IDSA 2014 SSTI Stevens PMID 24973422)
  • incision_and_drainage
    first line
    procedure
    procedural • single
    triggers: fluctuant_collection
    IDSA 2014 SSTI Stevens PMID 24973422 — I&D is primary curative therapy for any fluctuant cutaneous abscess; loop drainage or simple incision (packing optional, Gaspari Acad Emerg Med 2018 PMID 33037713)

outpatient playbook — drug actions (4)

  1. 1. Incision & drainage (loop or simple incision)
    n/a • procedural • single
    trigger: Fluctuant collection, mild/moderate, accessible site (IDSA 2014 SSTI Stevens PMID 24973422)
    Primary curative therapy; loop drainage equivalent to incision-and-packing with less pain (Gaspari Acad Emerg Med 2018 PMID 33037713)
  2. 2. TMP-SMX (adjunctive if moderate)
    1–2 DS PO • PO • BID × 5–7 d
    trigger: Size >2 cm / surrounding cellulitis / multiple / age extremes / diabetes / failed I&D (Talan NEJM 2016 PMID 26962903)
    Adjunctive cure +6.9% absolute; covers CA-MRSA
  3. 3. Clindamycin (TMP-SMX alternative / pregnancy / pediatric)
    300–450 mg PO • PO • QID × 5–7 d
    trigger: TMP-SMX intolerant, pregnant, pediatric (Daum NEJM 2017 PMID 28657870)
    Adjunctive cure +13–14% absolute; counsel C. difficile; check inducible resistance
  4. 4. Doxycycline (alternative)
    100 mg PO • PO • BID × 5–7 d
    trigger: TMP-SMX + clindamycin intolerant, non-pregnant ≥8 y (IDSA 2014 SSTI Stevens PMID 24973422)
    Alternative oral anti-MRSA

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Fluctuant, tender, erythematous nodule ± pointing/spontaneous drainage — cutaneous abscess (IDSA 2014 SSTI Stevens PMID 24973422 — purulent SSTI); Tender perifollicular pustule/nodule (furuncle) or coalesced multi-loculated mass with multiple draining sinuses (carbuncle) in hair-bearing skin (IDSA 2014 SSTI Stevens PMID 24973422); Recurrent painful nodules/abscesses with sinus tracts/scarring in axilla/groin/inframammary — recurrent furunculosis vs hidradenitis suppurativa pivot (Alikhan JAAD 2019 PMID 30872156).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cutaneous abscess / furuncle / carbuncle (I&D-primary purulent SSTI)** (derm.skin-abscess.core.v1).
Phenotype framing: Epidermal/sebaceous (epidermoid) cyst (inflamed vs infected), hidradenitis suppurativa, non-purulent cellulitis, necrotizing fasciitis, septic bursitis/arthritis, infected vascular access, pyomyositis, hematoma, lymphadenitis (IDSA 2014 SSTI Stevens PMID 24973422; Alikhan JAAD 2019 PMID 30872156)
Scope: Purulent vs non-purulent SSTI pivot (IDSA 2014 SSTI Stevens PMID 24973422 — distinct pathways); abscess/furuncle/carbuncle → I&D-primary; exclude necrotizing fasciitis (id.necrotising-fasciitis.core.v1) and non-purulent cellulitis (id.cellulitis.core.v1)

No severity triggers fired against current inputs.

Plan

Regimen axis: **I&D-primary + severity-tiered adjunctive antibiotics** — step "Mild — simple drained abscess, healthy host".
1. incision_and_drainage procedural single (procedure, first line) — IDSA 2014 SSTI Stevens PMID 24973422 — I&D is primary curative therapy for any fluctuant cutaneous abscess; loop drainage or simple incision (packing optional, Gaspari Acad Emerg Med 2018 PMID 33037713)

Setting playbook (outpatient) — Office/clinic I&D of mild–moderate abscess, decide adjunctive antibiotic, arrange 48–72 h recheck and recurrence-prevention (IDSA 2014 SSTI Stevens PMID 24973422)
2. Incision & drainage (loop or simple incision) n/a procedural single — Fluctuant collection, mild/moderate, accessible site (IDSA 2014 SSTI Stevens PMID 24973422) (Primary curative therapy; loop drainage equivalent to incision-and-packing with less pain (Gaspari Acad Emerg Med 2018 PMID 33037713))
3. TMP-SMX (adjunctive if moderate) 1–2 DS PO PO BID × 5–7 d — Size >2 cm / surrounding cellulitis / multiple / age extremes / diabetes / failed I&D (Talan NEJM 2016 PMID 26962903) (Adjunctive cure +6.9% absolute; covers CA-MRSA)
4. Clindamycin (TMP-SMX alternative / pregnancy / pediatric) 300–450 mg PO PO QID × 5–7 d — TMP-SMX intolerant, pregnant, pediatric (Daum NEJM 2017 PMID 28657870) (Adjunctive cure +13–14% absolute; counsel C. difficile; check inducible resistance)
5. Doxycycline (alternative) 100 mg PO PO BID × 5–7 d — TMP-SMX + clindamycin intolerant, non-pregnant ≥8 y (IDSA 2014 SSTI Stevens PMID 24973422) (Alternative oral anti-MRSA)

Non-pharmacologic actions:
- Wound care education + warm compresses for residual induration (IDSA 2014 SSTI Stevens PMID 24973422)
- Send wound culture if moderate/recurrent/immunocompromised/failed (IDSA 2014 SSTI Stevens PMID 24973422)
- Return precautions: fever, expanding erythema, increasing pain, systemic features
- Recurrent (≥2/yr) → decolonization counselling + HS reconsideration (Fritz CID 2012 PMID 22198793; Alikhan JAAD 2019 PMID 30872156)

AVOID / contraindication checks:
- Tmp smx avoid late pregnancy and G6PD and renal dose (IDSA 2014 SSTI Stevens PMID 24973422 — hyperkalemia/AKI/SJS; baseline creatinine)
- Doxycycline contraindicated pregnancy and children under 8 (IDSA 2014 SSTI Stevens PMID 24973422)
- Clindamycin c difficile counsel and D test inducible resistance (IDSA 2014 SSTI Stevens PMID 24973422)
- Vancomycin AUC target not trough and renal monitoring (IDSA 2020 vancomycin AUC consensus)
- Do not bedside incise if necrotizing suspected (IDSA 2014 SSTI Stevens PMID 24973422 — emergent surgery instead)

Monitoring

Regimen monitoring:
- wound recheck 48-72h response assessment (IDSA 2014 SSTI Stevens PMID 24973422)
- vancomycin AUC 24-48h when IV (IDSA 2020 vancomycin AUC consensus)
- creatinine and potassium on TMP-SMX (IDSA 2014 SSTI Stevens PMID 24973422)

Setting (outpatient) monitoring:
- Wound recheck 48–72 h (IDSA 2014 SSTI Stevens PMID 24973422)
- Reassess for inadequate drainage / retained loculation / resistant pathogen if not improving

Follow-up plan: ≥2 abscesses/year → MRSA decolonization (intranasal mupirocin 5 d + chlorhexidine body wash 5–14 d ± household + hygiene; oral rifampin-based only for refractory) (Fritz CID 2012 PMID 22198793; IDSA 2014 SSTI Stevens PMID 24973422); reconsider hidradenitis suppurativa if intertriginous recurrent with sinus tracts/scarring → route to HS chronic management (Alikhan JAAD 2019 PMID 30872156)
- Close-out criterion: recurrence-prevention / decolonization / HS-routing plan documented

Monitoring phase: Wound recheck 48–72 h (response = decreased erythema/pain/induration); reassess for inadequate drainage, retained loculation, resistant pathogen, or NF if not improving (IDSA 2014 SSTI Stevens PMID 24973422)

Disposition

Current setting: outpatient — Office/clinic I&D of mild–moderate abscess, decide adjunctive antibiotic, arrange 48–72 h recheck and recurrence-prevention (IDSA 2014 SSTI Stevens PMID 24973422)

Disposition criteria:
- Discharge after I&D if mild/moderate, no systemic toxicity, reliable follow-up (IDSA 2014 SSTI Stevens PMID 24973422)
- Refer/admit if danger-zone, perirectal/deep, large/multiple needing OR, severe class

Escalation triggers (move to higher acuity):
- Necrotizing features → emergent ED + surgery, do NOT incise (IDSA 2014 SSTI Stevens PMID 24973422)
- Systemic toxicity / failed outpatient I&D + oral → ED for IV anti-MRSA + admission

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Pain out of proportion, dusky/anaesthetic skin, hemorrhagic bullae, crepitus, "dishwater" drainage, or rapidly spreading erythema around the collection (IDSA 2014 SSTI Stevens PMID 24973422)
- [SEVERE] qSOFA ≥2 OR SIRS ≥2 with cutaneous abscess as the source (SSC 2026; IDSA 2014 SSTI Stevens PMID 24973422)
- [SEVERE] Facial danger triangle, perirectal/perineal, hand/deep palmar space, periorbital, or deep-space abscess (IDSA 2014 SSTI Stevens PMID 24973422)

Citations

- IDSA 2014 SSTI Guideline (Stevens et al, CID) purulent-SSTI pathway + Talan NEJM 2016 (TMP-SMX adjunct after I&D) + Daum NEJM 2017 (clindamycin/TMP-SMX adjunct, small abscess) + Schmitz Ann Emerg Med 2010 (no benefit, simple abscess) + Moran NEJM 2006 EMERGEncy ID Net (MRSA prevalence) + Gaspari Acad Emerg Med 2018 (loop drainage RCT) + Subramaniam Acad Emerg Med 2016 (POCUS meta) + Fritz CID 2012 (household MRSA decolonization) + Alikhan JAAD 2019 (HS management guideline) [PMID:24973422](https://pubmed.ncbi.nlm.nih.gov/24973422/)
- Cited evidence (PMID 26962903) [PMID:26962903](https://pubmed.ncbi.nlm.nih.gov/26962903/)
- Cited evidence (PMID 28657870) [PMID:28657870](https://pubmed.ncbi.nlm.nih.gov/28657870/)
- Cited evidence (PMID 20346539) [PMID:20346539](https://pubmed.ncbi.nlm.nih.gov/20346539/)
- Cited evidence (PMID 16914702) [PMID:16914702](https://pubmed.ncbi.nlm.nih.gov/16914702/)

Last reconciled with current guidelines: 2026-05-22.
References
  • IDSA 2014 SSTI Guideline (Stevens et al, CID) purulent-SSTI pathway + Talan NEJM 2016 (TMP-SMX adjunct after I&D) + Daum NEJM 2017 (clindamycin/TMP-SMX adjunct, small abscess) + Schmitz Ann Emerg Med 2010 (no benefit, simple abscess) + Moran NEJM 2006 EMERGEncy ID Net (MRSA prevalence) + Gaspari Acad Emerg Med 2018 (loop drainage RCT) + Subramaniam Acad Emerg Med 2016 (POCUS meta) + Fritz CID 2012 (household MRSA decolonization) + Alikhan JAAD 2019 (HS management guideline) — PMID:24973422
  • Cited evidence (PMID 26962903) — PMID:26962903
  • Cited evidence (PMID 28657870) — PMID:28657870
  • Cited evidence (PMID 20346539) — PMID:20346539
  • Cited evidence (PMID 16914702) — PMID:16914702